AZ hosted their Q4 ’17 earnings call (press release) and briefly discussed their diabetes portfolio, with a particular focus on Farxiga and Bydureon.
Merck hosted their Q4 ’17 earnings call and briefly discussed Januvia and the newly-approved Stegaltro franchise.
Biocon hosted its CY Q4 ’17 (FY Q3 ’18) earnings call and provided updates on its insulin portfolio including bs-glargine regulatory status, bs-aspart Ph1 initiation, and Tregopil (oral insulin) Ph2/3 initiation in India. Below are highlights from the call.
Abbott hosted its Q4 and full year 2017 earnings updates. Furthermore, Abbott provided an update on its recently launched Libre Consumer. Below are highlights from the call.
Novartis hosted its Q4 and full year 2017 earnings updates. Novartis briefly discussed its SGLT1/2i (LIK066), which is being developed for obesity. Of note, Novartis said it anticipates completing their Ph2b trial in H2 ’18 with Ph3 to potentially initiate as early as YE ’18 or early 2019. Below are highlights from the calls.
J&J hosted their Q4 ’17 earnings call and briefly discussed the diabetes business unit, including declining Invokana sales and the future of their diabetes device business. Notably, in response to analyst questions regarding potential diabetes divestitures, management was noncommittal.
Tandem Diabetes Care hosted its Q3 ’17 earnings call and provided updates to its pump business including the closed-loop programs. Below are highlights from the call.
Ionis hosted a Q2 ’17 earnings call and provided financial information for the quarter. During the call, Akcea financial highlights and product pipeline updates were provided. Recall, Akcea closed the company’s IPO at the end of July.
Tandem hosted their Q2 ’17 earnings call and issued a press release, providing financial updates as well as updates regarding t:slim LCM.
MannKind held its Q1 2017 earnings call and provided updates on commercial and clinical activities for Afrezza.